<DOC>
	<DOCNO>NCT02659033</DOCNO>
	<brief_summary>CEREMI open , randomise prospective study parallel group healthy volunteer . This study compare effect monotherapy ceftriaxone cefotaxime emergence resistance enterobacteria 3rd-generation cephalosporin within intestinal microbiota . Each volunteer treat 3 day either ceftriaxone ( 1 gram per day ) cefotaxime ( 1 gram every 8 hour ) .</brief_summary>
	<brief_title>Impact Choice 3rd Generation Cephalosporins Emergence Resistance Microbiota Intestinal .</brief_title>
	<detailed_description>Selection resistant bacteria within microbiota constitutes main mechanism emergence diffusion bacterial resistance antibiotic . Ceftriaxone 3rd generation cephalosporin expose intestinal microbiota important selecting pressure , due high biliary clearance . It thereby suspect important role emergence resistance enterobacteria 3rd generation cephalosporin . Its pharmacokinetics feature allow daily administration , largely used cefotaxime , require ter die injection whose mainly urinary elimination suggest low impact intestinal microbiota . Our hypothesis ceftriaxone exert high selecting pressure intestinal microbiota cefotaxime . Our main objective compare effect monotherapy ceftriaxone cefotaxime emergence resistance enterobacteria 3rd-generation cephalosporin within intestinal microbiota . Secondary objective include : - Comparison effect ceftriaxone cefotaxime count ( ) total enterobacteria , ( ii ) 3rd generation cephalosporin resistant enterobacteria accord resistance mechanism , ( iii ) colonisation resistance intestinal microbiota - Pharmacokinetic analysis cefotaxime ceftriaxone steady-state , link plasma fecal exposition antimicrobial - Analysis association individual exposition ceftriaxone cefotaxime impact intestinal microbiota . The main evaluation criterion area curve 3rd generation cephalosporin resistant enterobacteria intestinal microbiota D0 D7 . Secondary evaluation criterion include : - Bacterial fungal AUC ( area curve ) intestinal microbiota D0 D7 D0 D15 . Proportion patient 3rd generation cephalosporin resistant enterobacteria proportion patient non commensal bacteria fungi intestinal microbiota D30 , D90 D180 . - Studied pharmacokinetic parameter : total bocy clearance , volume distribution , half life . Studied plasma exposition parameter : AUC , maximal minimal concentration steady-state . Studied fecal exposition parameter : AUC D0 D7 . - Association plasma fecal exposure AUC bacterial fungal count D0 D7 . Methodology : Open , randomise prospective study parallel group healthy volunteer . Each volunteer treat 3 day either ceftriaxone ( 1 gram per day ) cefotaxime ( 1 gram every 8 hour ) . Fecal sample collect ( 3 sample , D-14 , D-7 D-1 ) first administration antibiotic ( D1 , D2 , D3 , D4 , D7 , D10 , D15 , D30 , D90 , D180 ) . Bacterial analysis fecal sample perform blindly treatment group . Drug plasma concentration determine steady-state ( T0 , T0.5h , T1h , T2h , T4 , T6h cefotaxime T0 , T0.5h , T1h , T2h , T4 , T8h ceftriaxone ) . Drug concentration feces measure sample obtain D0 D7 . Pharmacokinetic analysis perform use population approach . All statistical analysis perform use non parametric test .</detailed_description>
	<mesh_term>Ceftriaxone</mesh_term>
	<mesh_term>Cefotaxime</mesh_term>
	<mesh_term>Cefoxitin</mesh_term>
	<mesh_term>Cephalosporins</mesh_term>
	<criteria>Age 18 65 year Volunteer regard healthy detailed examination Subject whose entourage ( person live roof ) present chronic disease throughout course receive antibiotic within 15 day . Effective contraception woman reproductive age negative pregnancy test inclusion Normal intestinal passage ( one stool per day ) Negative urinalysis toxic substance Normal blood test ( include blood platelet count , prothrombin , ionograms , Liver function test ) Negative HIV HCV ( hepatitis C virus ) test , HBV ( hepatitis B virus ) chronic infection Normal weight ( BMI comprise 19 29 kg/m² ) Freely obtain consent Health insurance beneficiary Antibiotic therapy previous 6 month Hospitalisation previous 12 month ; Active infection Ongoing treatment Any chronic disease Allergy one study drug Any contraindication βlactam therapy particular penicillin cephalosporin Pregnancy effective contraception , suckle woman Subject , determine investigate physician , could observe study , unable communicate language mental disorder barrier ; Subject participate simultaneously another biomedical research Subject contact case emergency ; Subject legally protect tutorship curator ; Subject deprive freedom judicial administrative constraint Secondary exclusion criterion No pretreatment stool sample obtain More one stool sample miss D1 D7</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>microbiota</keyword>
	<keyword>resistant bacteria</keyword>
</DOC>